Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 eldn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to in
EX-99.1 2 eldn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data presented at ATC 2026 demonstrated sustained higher kidney function and improved patient-reported outcomes with tegoprubart compared with tacrolimus Updated islet cell transplantation data presented at ADA 2026 showed 100% insulin independence in all 12 patients with type 1 diabetes Cash, cash equivalents and short-term investments of $88.8 million as of June 30, 2026 IRVINE, Calif., August 13, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its second quarter 2026 operating and financial results a...
Source
Exhibit EX-99.1
0001193125-26-349170
Filed August 13, 2026 at 8:08 PM UTC. The figures above are from the audited statements, not from this release.